Biogen Inc vs Clear Secure Inc — how do they compare? Biogen Inc trades at $191.4 (market cap $30.86B), while Clear Secure Inc trades at $54.42 (market cap $5.35B). The key difference: Biogen Inc is far larger — about 5.8× Clear Secure Inc's market cap, and Clear Secure Inc pays a 1.13% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | YOU | |
|---|---|---|
Market Cap | $30.86B | $5.35B |
Sector | Health | Technology |
52-Week High | $216.63 | $62.36 |
52-Week Low | $122.68 | $28.84 |
Enterprise Value | $33.14B | $4.66B |
Dividend Yield | — | 1.13% |
Trailing returns across standard periods
Latest headlines on both assets
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →